Literature DB >> 17005793

Clonal analysis of Inquilinus limosus isolates from six cystic fibrosis patients and specific serum antibody response.

Sabine Schmoldt1, Philipp Latzin2, Juergen Heesemann1, Matthias Griese2, Axel Imhof3, Michael Hogardt1.   

Abstract

Inquilinus limosus is a novel Gram-negative bacterium of the subdivision alpha-Proteobacteria recently found in the airways of patients with cystic fibrosis (CF). Here, the authors report on the clinical courses of six CF patients colonized with I. limosus. Five patients suffered from either an acute respiratory exacerbation or a progressive loss of pulmonary function, whereas one patient was in a stable clinical situation. This study focused on two aims: (i) the clonal analysis of I. limosus isolates by random amplified polymorphic DNA (RAPD)-PCR, and (ii) the clarification of whether the presence of I. limosus in the respiratory tract is associated with a specific serum antibody response. Serum IgG was detected by immunoblotting using I. limosus whole-cell-lysate proteins as antigens. Sera from healthy blood donors (n=10) and from CF patients colonized with Pseudomonas aeruginosa (n=10) were found to be immunoblot negative. All six Inquilinus-positive patients raised serum IgG antibodies against various I. limosus antigens. Surprisingly, in one patient, a specific I. limosus serum antibody response was already detected 1 year prior to Inquilinus-positive sputum cultures. Two prominent antigens were characterized by MALDI-MS: a 23 kDa protein revealed homology to the outer membrane lipoprotein OmlA of Actinobacillus pleuropneumoniae, and an 18 kDa protein to a protein-tyrosine phosphatase of Burkholderia cepacia. In conclusion, detection of I. limosus is accompanied by a specific serum antibody response and may reflect the infectious/pathogenic potential of I. limosus. Moreover, IgG immunoblotting may be useful to detect early infection with I. limosus and may support the selective cultivation of this novel emerging pathogen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005793     DOI: 10.1099/jmm.0.46466-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates.

Authors:  Michael Hogardt; Jutta Ulrich; Helga Riehn-Kopp; Burkhard Tümmler
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

4.  Host genetic variation in mucosal immunity pathways influences the upper airway microbiome.

Authors:  Catherine Igartua; Emily R Davenport; Yoav Gilad; Dan L Nicolae; Jayant Pinto; Carole Ober
Journal:  Microbiome       Date:  2017-02-01       Impact factor: 14.650

5.  Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.

Authors:  T Spencer Poore; Isabel Virella-Lowell; Jennifer S Guimbellot
Journal:  Pediatr Pulmonol       Date:  2018-05-23

6.  Inquilinus limosus and cystic fibrosis.

Authors:  Fadi Bittar; Anne Leydier; Emmanuelle Bosdure; Alexandre Toro; Martine Reynaud-Gaubert; Stéphanie Boniface; Nathalie Stremler; Jean-Christophe Dubus; Jacques Sarles; Didier Raoult; Jean-Marc Rolain
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

7.  Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients.

Authors:  Fadi Bittar; Hervé Richet; Jean-Christophe Dubus; Martine Reynaud-Gaubert; Nathalie Stremler; Jacques Sarles; Didier Raoult; Jean-Marc Rolain
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

Review 8.  Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.

Authors:  Dinesh Sriramulu
Journal:  Microbiol Insights       Date:  2013-04-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.